Assess the Risk of Cerebrovascular Disease

NCT04443439 · tracked via the Priya Life Science China tracker

Sponsor

Tang-Du Hospital

Phase

Observational

Started

2020-10-09

Last updated

2022-10-25

Condition(s) studied

Cerebrovascular Disease

Investigational drug(s) / intervention(s)

GE Discovery MR750 3.0t superconducting MRI

GE Discovery MR750 3.0t superconducting MRI: T2WI, FLAIR, DWI, 3D BRAVO, 3D-ASL, rs-fMRI, DKI sequences to exclude other organic lesions

Study summary

Intracranial artery stenosis is an important cause of ischemic stroke, but the degree of intracranial artery stenosis is not completely matched with the symptoms of ischemic stroke. Asymptomatic carotid stenosis (ACS) refers to does not appear related neurological symptoms of carotid stenosis and stroke or transient ischemic attack of carotid stenosis, did not happen cerebrovascular events such as stroke, but there have been a different degree of cognitive impairment, be badly in need of development of noninvasive imaging methods, objective evaluation of the ACS group cognitive impairment, and predict the ACS risk of ischemic stroke. Therefore, this topic proposed comprehensive cognitive assessment, CTA, double modal MRI techniques, clinical and biochemical indicator detection, mathematical modeling and statistical analysis techniques, assess the ACS group and normal person the cognitive ability, the difference of NVC and local perfusion, and follow-up ACS crowd of ischemic stroke and other cardiovascular events, discuss ACS and cognitive impairment, the correlation of NVC and local perfusion abnormalities, screening of radiographic predictor of ischemic stroke, and in the follow-up of ACS population in testing the sensitivity of the series of indicators and specific degrees.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Mild stenosis group: CTA suggested carotid stenosis \< 30%; 2. Moderate stenosis group: CTA suggested carotid stenosis of 30-69%; 3. Severe stenosis group: CTA indicated carotid stenosis ≥70%; Exclusion Criteria: 1. dementia, MMSE score \< 21; 2. previous carotid stenosis related neurological symptoms or transient ischemic attack; 3. other craniocerebral lesions, such as craniocerebral trauma, tumor, inflammation, and complications of great vessels (cerebral infarction or cerebral malacia); 4. contraindications for MRI examination; 5. recent use of psychoactive drugs or hormones.

Primary outcome measure(s)

Dynamic change and correlation analysis of multi-dimensional features of ACS degree and cognitive impairment — 2020.01
The Montreal cognitive assessment (MoCA) scale was used to evaluate the differences in cognitive function between ACS and the healthy control group in different dimensions, and the horizontal correlation analysis between ACS and cognitive impairment was conducted according to the dimensions of cognitive impairment and the degree of ACS.

Trial sites (1)

Facility	City	Region	Status
Wen Wang	Xi'an	China	Recruiting

More Tang-Du Hospital trials in China

Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial Starting soon

Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIA-IIIB Resectable NSCLC (FORESEE) Active, not recruiting

Bristol Stool Scale-Based Care Pathway for Enteral Nutrition-Associated Diarrhea in Critically Ill Patients Starting soon

Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer Recruiting

Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer Starting soon

Other trials for the same condition

Application of QDSA Platform in Cerebrovascular Diseases Recruiting

(Withdrawal) AI-Based Low-Dose 3D-DSA Reconstruction Starting soon

Diabetes Complications and the Risk of Cardiovascular and Cerebrovascular Diseases Starting soon

Safety and Efficacy of Enhanced Recovery After Surgery in Neurocritical Care Recruiting

Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study) Enrolling by invitation

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04443439 on ClinicalTrials.gov ↗ ← All trials in China